Visceral crisis in a patient with non-small cell lung cancer and ROS1::SDC4 fusion: intrinsic resistance to entrectinib via L2026M mutation—a case report
The emergence of the L2026M mutation suggests a need for next-generation TKIs and combination strategies to overcome resistance. Future studies should explore novel inhibitors targeting ROS1 resistance pathways to improve outcomes in this subset of NSCLC patients.
Authors
- Luis Corrales (ORCID: https://orcid.org/0000-0001-9732-5693)
- Leonardo Rojas (ORCID: https://orcid.org/0000-0002-7865-5424)
- Carlos Carvajal (ORCID: https://orcid.org/0000-0001-5915-0052)
- Óscar Arrieta (ORCID: https://orcid.org/0000-0002-1164-3779)
- Javier León (ORCID: https://orcid.org/0000-0001-5803-0112)
- Alejandro Ruíz-Patiño (ORCID: https://orcid.org/0000-0003-1274-9273)
- Stella Isabel Martínez-Jaramillo (ORCID: https://orcid.org/0000-0002-4376-7119)
- Claudio Martín (ORCID: https://orcid.org/0000-0003-4135-7332)
- Andrés F. Cardona (ORCID: https://orcid.org/0000-0003-3525-4126)
- Lucía Viola (ORCID: https://orcid.org/0000-0002-1647-2884)
- Nicolle Wagner-Gutiérrez (ORCID: https://orcid.org/0000-0002-2015-1901)
- V. Rodríguez (ORCID: https://orcid.org/0000-0003-3476-970X)
Institutions
- Foundation for Clinical and Applied Cancer Research (CO)
Publication Details
- Journal
- Translational Lung Cancer Research
- Published
- 2025-05-01
- DOI
- https://doi.org/10.21037/tlcr-2024-1149
- Primary Topic
- Lung Cancer Treatments and Mutations
- Type
- article
- Field-Weighted Citation Impact
- 0.00